Format

Send to

Choose Destination
Front Microbiol. 2018 May 15;9:980. doi: 10.3389/fmicb.2018.00980. eCollection 2018.

Oropharyngeal Candidosis in HIV-Infected Patients-An Update.

Author information

1
Division of Oral Pathology, Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Jizan, Saudi Arabia.
2
Department of Oral Pathology and Microbiology, Bhojia Dental College & Hospital, Baddi, India.
3
Department of Oral Pathology and Microbiology, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, India.
4
College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, United States.

Abstract

Oropharyngeal candidosis (OPC) is an opportunistic fungal infection that is commonly found in HIV-infected patients, even in the twenty-first century. Candida albicans is the main pathogen, but other Candida species have been isolated. OPC usually presents months or years before other severe opportunistic infections and may indicate the presence or progression of HIV disease. The concept of OPC as a biofilm infection has changed our understanding of its pathobiology. Various anti-fungal agents (both topical and systemic) are available to treat OPC. However, anti-fungal resistance as a result of the long-term use of anti-fungal agents and recurrent oropharyngeal infection in AIDS patients require alternative anti-fungal therapies. In addition, both identifying the causative Candida species and conducting anti-fungal vulnerability testing can improve a clinician's ability to prescribe effective anti-fungal agents. The present review focuses on the current findings and therapeutic challenges for HIV-infected patients with OPC.

KEYWORDS:

AIDS; Candida; HIV; Oropharyngeal candidosis; antifungals; opportunistic infections

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center